If enacted, HB 8297 would amend existing laws governing the dispensing of controlled substances, particularly focusing on opioids. It emphasizes the need for prescribers to document their discussions regarding addiction risks, thereby improving accountability and supporting patient health outcomes. The changes brought by the bill would align with ongoing efforts to address the opioid crisis by ensuring that patients are adequately informed about the potential risks associated with these powerful medications.
Summary
House Bill 8297, relating to the Uniform Controlled Substances Act, aims to enhance regulations surrounding the prescription of opioid drugs in Rhode Island. The bill stipulates that healthcare professionals authorized to prescribe controlled substances must discuss addiction risks with patients or their parents/guardians if they are under the age of eighteen. This requirement seeks to inform patients about the dangers of developing dependencies on prescribed medications and to encourage the exploration of alternative treatment options when appropriate.
Contention
The bill has generated discussions regarding its potential implications for prescriber-patient relationships. Supporters argue that mandating discussions about addiction risks is a crucial step in combating opioid misuse and protecting vulnerable populations, particularly minors. On the other hand, some healthcare professionals express concern that this requirement could add to the administrative burden and discourage prescribers from appropriately managing pain in patients who genuinely need opioid medications. Thus, the balance between ensuring patient safety and preserving effective pain management practices remains a notable point of contention among stakeholders.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements and revises the uniform controlled substances act in accordance with current standards of professional practice.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements and revise the uniform controlled substances act in accordance with current standards of professional practice.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.
Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.